For AI assistants & researchers — machine-readable summary of this page
What this page is: Delvantic's full research page for DaVita Inc. (DVA) — AI-driven forensic equity research: mechanical valuation models (DCF, EPV, anchored-PE, scenario) plus three independent AI lenses (Quality / Value / Sentiment). Everything below is rendered server-side; you are not missing content that requires JavaScript. All scores are predictions and research opinions, not financial advice.
Page map (sections in order; each card carries a stable
reference-name attribute you can cite):
profile-header/price-overview— company profile, live quote, market capextended-analysis— the core: three AI lens reads with findings, scores, and the analyst memofuture-predictions— our forward price-band predictionsmarket-narrative/ai-findings/gpt-critique— narrative context, cross-model findings, and an adversarial critique of our own analysis (near the end of the document)- Members-only sections (render as login gates for anonymous readers):
price-history,income-trend,key-metrics,financials(statement tables),insider-trading. The analysis above is public; the raw data tables require a free account.
More for machine readers: site briefing at
/llms.txt ·
any ticker resolves at delvantic.com/stock/TICKER ·
raw inputs are public-company filings and market data (via licensed data feeds);
every model, score, lens read, and prediction on this page is Delvantic's own analysis.
DaVita Inc. is a healthcare services company specializing in kidney care, with a primary focus on providing dialysis treatments for patients with chronic kidney failure and end-stage renal disease. The company operates a large network of outpatient dialysis centers, where it delivers in-center hemodialysis and related care services to adult patients across the United States and internationally. DaVita Inc. also supports home-based dialysis modalities, offering peritoneal dialysis and home hemodialysis, along with clinical education and support programs to help patients manage treatment outside the clinic setting. In addition, the company operates clinical laboratories that perform routine and specialized tests for dialysis patients and provides management and administrative services to affiliated outpatient centers. Headquartered in Denver, Colorado, DaVita Inc. plays a significant role in the healthcare system by serving a critical, medically complex patient population and working alongside physicians, hospitals, and payers to coordinate kidney care and related services.
Earnings Schedule
Checked daily · calendar updated Aug 11| Print date | EPS est. | EPS actual | Revenue est. | Revenue actual |
|---|---|---|---|---|
| Aug 4, 2026 | $3.88 | $4.02 +3.6% | — | — |
| Jun 25, 2026 | $-0.14 | $-0.16 -14.3% | — | — |
| May 29, 2026 | $0.74 | $0.92 +24.3% | — | — |
| May 5, 2026 | $2.33 | $2.87 +23.2% | — | — |
Green = beat the estimate, red = missed. An earnings print is the fastest way a thesis changes — our designations should be re-read after each one.
Recent SEC Filings
| Filed | Form | Document |
|---|---|---|
| Aug 4, 2026 | 4 | View |
| Aug 4, 2026 | 10-Q | View |
| Aug 4, 2026 | 8-K | View |
| Jun 17, 2026 | 4 | View |
| Jun 17, 2026 | 4 | View |
| Jun 17, 2026 | 11-K | View |
| Jun 16, 2026 | 144 | View |
| Jun 15, 2026 | 144 | View |
| Jun 15, 2026 | 144 | View |
| Jun 15, 2026 | 144 | View |
| Jun 8, 2026 | 8-K | View |
| May 28, 2026 | 4 | View |
Filings link to the SEC’s EDGAR system. Annual/quarterly reports (10-K, 10-Q, 20-F) carry the full story; 8-K/6-K current reports are the fastest signal that something material happened.
Price Overview
Last updated: Aug 11, 2026 11:04am (just now)Price History (1 Year)
Revenue & Net Income Trend
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
EPS (Diluted): 9.84
Total Equity: $1.16B
Shares: 75,885,000
Total Debt: $0.00
Cash: $676.44M
EBITDA: $2.75B
Total Debt: $0.00
Cash: $676.44M
Revenue: $13.64B
Revenue: $13.64B
Revenue: $13.64B
Total Equity: $1.16B
Tax Rate: 21.8%
Equity: $1.16B
Total Debt: $0.00
Cash: $676.44M
Current Liabilities: $3.14B
Long-Term Debt: $0.00
Total Debt: $0.00
Total Equity: $1.16B
Shares: 75,885,000
Shares: 75,885,000
CapEx: -$575.86M
Shares: 75,885,000
Stock Price: $181.21
Net Income: $746.80M
Income Statement (Annual)
Last updated: Aug 9, 2026 12:44pm (1d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $11.6B | $11.6B | $12.1B | $12.8B | $13.6B |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Expenses | $9.8B | $10.3B | $10.5B | $10.7B | $11.6B |
| Operating Income | $1.8B | $1.3B | $1.6B | $2.1B | $2.0B |
| Net Income | $978.5M | $560.4M | $691.5M | $936.3M | $746.8M |
| EBITDA | $2.5B | $2.1B | $2.3B | $2.8B | $2.8B |
| EPS | $9.30 | $6.03 | $7.62 | $11.02 | $10.06 |
| EPS (Diluted) | $8.90 | $5.85 | $7.42 | $10.73 | $9.84 |
Balance Sheet (Annual)
Last updated: Aug 9, 2026 12:44pm (1d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $461.9M | $244.1M | $380.1M | $794.9M | $676.4M |
| Total Current Assets | $3.2B | $3.2B | $3.1B | $3.7B | $4.1B |
| Total Assets | $17.1B | $16.9B | $16.9B | $17.3B | $17.5B |
| Current Liabilities | $2.4B | $2.6B | $2.6B | $3.0B | $3.1B |
| Long-Term Debt | — | — | — | — | — |
| Total Liabilities | $14.8B | $14.7B | $14.2B | $15.2B | $16.3B |
| Total Equity | $2.4B | $2.2B | $2.7B | $2.1B | $1.2B |
| Retained Earnings | $354.3M | $174.5M | $598.3M | $1.5B | -$328.4M |
Cash Flow (Annual)
Last updated: Aug 9, 2026 12:44pm (1d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $1.9B | $1.6B | $2.1B | $2.0B | $1.9B |
| Capital Expenditure | -$641.5M | -$603.4M | -$568.0M | -$555.4M | -$575.9M |
| Free Cash Flow | $1.3B | $961.1M | $1.5B | $1.5B | $1.3B |
| Acquisitions (net) | — | -$57.3M | -$26.4M | -$246.1M | -$117.5M |
| Net Debt Issued / (Repaid) | $1.6B | $2.4B | $2.5B | $6.6B | $5.6B |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 |
| Stock Buybacks | -$1.5B | -$802.2M | -$272.2M | -$1.4B | -$1.3B |
| Net Change in Cash | $53.2M | -$216.0M | $125.6M | $415.2M | -$122.1M |
Growth Trends (YoY %)
Last updated: Aug 9, 2026 12:44pm (1d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | -0.1% | +4.6% | +5.6% | +6.5% |
| Gross Profit Growth | — | — | — | — |
| Operating Income Growth | -25.5% | +19.7% | +30.4% | -2.2% |
| Net Income Growth | -42.7% | +23.4% | +35.4% | -20.2% |
| EBITDA Growth | -16.4% | +13.5% | +20.0% | -2.0% |
Industry Benchmarks
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
Narrative Economics
market-narrative step).
Claude Reading
ai-findings step) when a report is run on this ticker.
GPT Reading
gpt-critique step) after the other Big-3 seats, when a
report is run on this ticker.
Grok Reading
grok-critique step) alongside the other Big-3 seats, when a
report is run on this ticker.